The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Angioplasty, Transluminal, Percutaneous Coronary

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Angioplasty, Transluminal, Percutaneous Coronary


Psychiatry related information on Angioplasty, Transluminal, Percutaneous Coronary

  • RESULTS: Women treated with pravastatin had a risk reduction of 43% for the primary end point (p = 0.035), 46% for combined coronary events (p = 0.001), 48% for PTCA (p = 0.025), 40% for CABG (p = 0.14) and 56% for stroke (p = 0.07) [6].
  • In conclusion, this study shows that PFA-100 may be helpful in the decision making for additional antiaggregant therapy before PTCA or in monitoring long-term GPIIb/IIIa receptor antagonist treatment [7].

High impact information on Angioplasty, Transluminal, Percutaneous Coronary

  • Intracranial bleeding occurred more frequently among patients who received t-PA than among those who underwent PTCA (2.0 vs. 0 percent, P = 0.05) [1].
  • Eight hours before PTCA, the oral dipyridamole was replaced with intravenous dipyridamole at a dosage of 10 mg per hour for 24 hours, and oral aspirin was continued [8].
  • CONTEXT: The direct thrombin inhibitor bivalirudin has been associated with better efficacy and less bleeding than heparin during coronary balloon angioplasty but has not been widely tested during contemporary percutaneous coronary intervention (PCI) [9].
  • CONCLUSIONS: Creatine kinase elevation following elective PTCA is associated with increased late cardiac mortality [10].
  • Furthermore, markers of leukocyte activation - in particular, increased expression of the beta2-integrin Mac-1 (alphaMbeta2, or CD11b/CD18), which is responsible for firm leukocyte adhesion to platelets and fibrinogen on denuded vessels - predict restenosis after PTCA [11].

Chemical compound and disease context of Angioplasty, Transluminal, Percutaneous Coronary


Biological context of Angioplasty, Transluminal, Percutaneous Coronary


Anatomical context of Angioplasty, Transluminal, Percutaneous Coronary


Associations of Angioplasty, Transluminal, Percutaneous Coronary with chemical compounds


Gene context of Angioplasty, Transluminal, Percutaneous Coronary

  • CONCLUSIONS: The increase in TxA(2) during PTCA is primarily COX-1 dependent, and aspirin alone is effective in suppressing its formation [28].
  • Percent change in the expression of CD18 at 48 h after PTCA (from baseline) and that of CD11b were correlated (r = 0.73, p = 0.0008) in patients with restenosis [29].
  • Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor [28].
  • On the other hand, plasma MCP-1 levels did not change significantly during a 24-h observation period after PTCA [30].
  • Plasma MMP-2/TIMP-2 ratio and MMP-2 activity in the coronary sinus showed significant increases 4 and 24 h after PTCA [31].

Analytical, diagnostic and therapeutic context of Angioplasty, Transluminal, Percutaneous Coronary


  1. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. Grines, C.L., Browne, K.F., Marco, J., Rothbaum, D., Stone, G.W., O'Keefe, J., Overlie, P., Donohue, B., Chelliah, N., Timmis, G.C. N. Engl. J. Med. (1993) [Pubmed]
  2. Emergency coronary angioplasty in refractory unstable angina. de Feyter, P.J., Serruys, P.W., van den Brand, M., Balakumaran, K., Mochtar, B., Soward, A.L., Arnold, A.E., Hugenholtz, P.G. N. Engl. J. Med. (1985) [Pubmed]
  3. Adjunctive intracoronary infusion of antithrombin III during percutaneous transluminal coronary angioplasty. Results of a prospective, randomized trial. Schächinger, V., Allert, M., Kasper, W., Just, H., Vach, W., Zeiher, A.M. Circulation (1994) [Pubmed]
  4. Silent myocardial ischemia in Kawasaki disease: evaluation of percutaneous transluminal coronary angioplasty by dobutamine stress testing. Ogawa, S., Fukazawa, R., Ohkubo, T., Zhang, J., Takechi, N., Kuramochi, Y., Hino, Y., Jimbo, O., Katsube, Y., Kamisago, M., Genma, Y., Yamamoto, M. Circulation (1997) [Pubmed]
  5. Preconditioning of human myocardium with adenosine during coronary angioplasty. Leesar, M.A., Stoddard, M., Ahmed, M., Broadbent, J., Bolli, R. Circulation (1997) [Pubmed]
  6. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. Lewis, S.J., Sacks, F.M., Mitchell, J.S., East, C., Glasser, S., Kell, S., Letterer, R., Limacher, M., Moye, L.A., Rouleau, J.L., Pfeffer, M.A., Braunwald, E. J. Am. Coll. Cardiol. (1998) [Pubmed]
  7. Use of the PFA-100 apparatus to assess platelet function in patients undergoing PTCA during and after infusion of c7E3 Fab in the presence of other antiplatelet agents. Hézard, N., Metz, D., Nazeyrollas, P., Droulle, C., Elaerts, J., Potron, G., Nguyen, P. Thromb. Haemost. (2000) [Pubmed]
  8. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. Schwartz, L., Bourassa, M.G., Lespérance, J., Aldridge, H.E., Kazim, F., Salvatori, V.A., Henderson, M., Bonan, R., David, P.R. N. Engl. J. Med. (1988) [Pubmed]
  9. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. Lincoff, A.M., Bittl, J.A., Harrington, R.A., Feit, F., Kleiman, N.S., Jackman, J.D., Sarembock, I.J., Cohen, D.J., Spriggs, D., Ebrahimi, R., Keren, G., Carr, J., Cohen, E.A., Betriu, A., Desmet, W., Kereiakes, D.J., Rutsch, W., Wilcox, R.G., de Feyter, P.J., Vahanian, A., Topol, E.J. JAMA (2003) [Pubmed]
  10. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. Kong, T.Q., Davidson, C.J., Meyers, S.N., Tauke, J.T., Parker, M.A., Bonow, R.O. JAMA (1997) [Pubmed]
  11. Decreased neointimal formation in Mac-1(-/-) mice reveals a role for inflammation in vascular repair after angioplasty. Simon, D.I., Dhen, Z., Seifert, P., Edelman, E.R., Ballantyne, C.M., Rogers, C. J. Clin. Invest. (2000) [Pubmed]
  12. Angiotensin-converting enzyme and apolipoprotein E genotypes and restenosis after coronary angioplasty. van Bockxmeer, F.M., Mamotte, C.D., Gibbons, F.A., Burke, V., Taylor, R.R. Circulation (1995) [Pubmed]
  13. Changing features of anginal pain after PTCA suggest a stenosis on a different artery rather than restenosis. Pasceri, V., Patti, G., Maseri, A. Circulation (1997) [Pubmed]
  14. Left ventricular performance, regional blood flow, wall motion, and lactate metabolism during transluminal angioplasty. Serruys, P.W., Wijns, W., van den Brand, M., Meij, S., Slager, C., Schuurbiers, J.C., Hugenholtz, P.G., Brower, R.W. Circulation (1984) [Pubmed]
  15. Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty. Desmet, W., Vrolix, M., De Scheerder, I., Van Lierde, J., Willems, J.L., Piessens, J. Circulation (1994) [Pubmed]
  16. Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty. Langford, E.J., Brown, A.S., Wainwright, R.J., de Belder, A.J., Thomas, M.R., Smith, R.E., Radomski, M.W., Martin, J.F., Moncada, S. Lancet (1994) [Pubmed]
  17. Coronary artery vasoconstriction routinely occurs after percutaneous transluminal coronary angioplasty. A quantitative arteriographic analysis. Fischell, T.A., Derby, G., Tse, T.M., Stadius, M.L. Circulation (1988) [Pubmed]
  18. Concept of maximal flow ratio for immediate evaluation of percutaneous transluminal coronary angioplasty result by videodensitometry. Pijls, N.H., Aengevaeren, W.R., Uijen, G.J., Hoevelaken, A., Pijnenburg, T., van Leeuwen, K., van der Werf, T. Circulation (1991) [Pubmed]
  19. Frequency distribution of collateral flow and factors influencing collateral channel development. Functional collateral channel measurement in 450 patients with coronary artery disease. Pohl, T., Seiler, C., Billinger, M., Herren, E., Wustmann, K., Mehta, H., Windecker, S., Eberli, F.R., Meier, B. J. Am. Coll. Cardiol. (2001) [Pubmed]
  20. Myocardial perfusion imaging with thallium-201 to evaluate patients before and after percutaneous transluminal coronary angioplasty. DePuey, E.G. Circulation (1991) [Pubmed]
  21. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Jones, D.A., Benjamin, C.W., Linseman, D.A. Mol. Pharmacol. (1995) [Pubmed]
  22. Serum prostaglandin D synthase level after coronary angioplasty may predict occurrence of restenosis. Inoue, T., Takayanagi, K., Morooka, S., Uehara, Y., Oda, H., Seiki, K., Nakajima, H., Urade, Y. Thromb. Haemost. (2001) [Pubmed]
  23. Stimulation of the proliferation and differentiation of mouse pink-eyed dilution epidermal melanocytes by excess tyrosine in serum-free primary culture. Hirobe, T., Wakamatsu, K., Ito, S., Abe, H., Kawa, Y., Mizoguchi, M. J. Cell. Physiol. (2002) [Pubmed]
  24. Chimeric DNA-RNA hammerhead ribozyme targeting PDGF A-chain mRNA specifically inhibits neointima formation in rat carotid artery after balloon injury. Kotani, M., Fukuda, N., Ando, H., Hu, W.Y., Kunimoto, S., Saito, S., Kanmatsuse, K. Cardiovasc. Res. (2003) [Pubmed]
  25. Evidence for altered epicardial coronary artery autoregulation as a cause of distal coronary vasoconstriction after successful percutaneous transluminal coronary angioplasty. Fischell, T.A., Bausback, K.N., McDonald, T.V. J. Clin. Invest. (1990) [Pubmed]
  26. Coronary stenting decreases restenosis in lesions with early loss in luminal diameter 24 hours after successful PTCA. Rodriguez, A.E., Santaera, O., Larribau, M., Fernandez, M., Sarmiento, R., Perez Baliño, n.u.l.l., Newell, J.B., Roubin, G.S., Palacios, I.F. Circulation (1995) [Pubmed]
  27. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy. Mascelli, M.A., Worley, S., Veriabo, N.J., Lance, E.T., Mack, S., Schaible, T., Weisman, H.F., Jordan, R.E. Circulation (1997) [Pubmed]
  28. Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor. Kearney, D., Byrne, A., Crean, P., Cox, D., Fitzgerald, D.J. J. Am. Coll. Cardiol. (2004) [Pubmed]
  29. Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty. Inoue, T., Sakai, Y., Morooka, S., Hayashi, T., Takayanagi, K., Takabatake, Y. J. Am. Coll. Cardiol. (1996) [Pubmed]
  30. Chemokine expression in coronary circulation after coronary angioplasty as a prognostic factor for restenosis. Hojo, Y., Ikeda, U., Katsuki, T., Mizuno, O., Fukazawa, H., Fujikawa, H., Shimada, K. Atherosclerosis (2001) [Pubmed]
  31. Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. Hojo, Y., Ikeda, U., Katsuki, T., Mizuno, O., Fujikawa, H., Shimada, K. Atherosclerosis (2002) [Pubmed]
  32. Limitations of the electrocardiogram in estimating infarction size after acute reperfusion therapy for myocardial infarction. Christian, T.F., Clements, I.P., Behrenbeck, T., Huber, K.C., Chesebro, J.H., Gersh, B.J., Gibbons, R.J. Ann. Intern. Med. (1991) [Pubmed]
  33. A comparison of the costs of and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease. Results from the Emory Angioplasty Versus Surgery Trial (EAST). Weintraub, W.S., Mauldin, P.D., Becker, E., Kosinski, A.S., King, S.B. Circulation (1995) [Pubmed]
  34. Do fish oils prevent restenosis after coronary angioplasty? Leaf, A., Jorgensen, M.B., Jacobs, A.K., Cote, G., Schoenfeld, D.A., Scheer, J., Weiner, B.H., Slack, J.D., Kellett, M.A., Raizner, A.E. Circulation (1994) [Pubmed]
WikiGenes - Universities